{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Neumora Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"NMRA"},"Address":{"label":"Address","value":"490 ARSENAL WAY,SUITE 200, WATERTOWN, Massachusetts, 02472, United States"},"Phone":{"label":"Phone","value":"857-760-0900"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; NMRA-266 for the treatment of schizophrenia and other neuropsychiatric disorders; NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021."},"CompanyUrl":{"label":"Company Url","value":"https://www.neumoratx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Carol Suh","title":"Chief Operating Officer"},{"name":"Henry O. Gosebruch","title":"President, Chief Executive Officer & Director"},{"name":"Nicholas Brandon","title":"Chief Scientific Officer"},{"name":"Raj Manchanda","title":"Chief Technical Operations Officer"},{"name":"Robert Lenz","title":"Head-Research & Development"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}